在渐进性IgA病症上,奥比努祖马布的有效性和安全性:一个病例系列
Qingyun Ding1, Cheng Xue1, Xiang Gao1,2
1Division of Nephrology, Kidney Institute of PLA of China, Shanghai Changzheng Hospital, Second Affiliated Hospital of Naval Medical University (Second Military Medical University), Shanghai, China.
Journal of nephrology
|October 9, 2025
概括
一种抗CD20抗体Obinutuzumab在通过消耗B细胞来治疗IgA脏病 (IgAN) 方面表现有前途. 这一案例系列表明,奥比努图祖马布可以改善功能,并减少对其他疗法耐药的Igan患者的蛋白尿症.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- IgA病 (IgAN) 是全世界衰竭的主要原因.
- 通过IgA的产生,B细胞在IgAN的发病过程中起着至关重要的作用.
- 像Rituximab这样的当前治疗方法有局限性;奥比努图祖马布有可能增强B细胞枯竭.
研究的目的:
- 评估在患有进展性IgAN的患者中奥比努祖马布的疗效和安全性.
- 评估奥比努图祖马布对B细胞枯竭,蛋白尿,血液和功能的影响.
- 探索obinutuzumab作为对其他免疫抑制剂耐受性IGAN治疗的治疗选择.
主要方法:
- 三名患有进展性IgAN的患者的病例系列.
- 患者在其他免疫抑制疗法失败后接受了奥比努祖马布 (1000毫克,1-2剂量).
- 评估结果包括12个月的B细胞枯竭,蛋白尿,血液和功能.
主要成果:
- 所有患者都实现了持续的B细胞枯竭.
- 观察到蛋白尿和血液尿的显著减少.
- 功能得到改善和IgA/C3沉积减少.
- 发生了轻微的输液反应,但没有报告严重的不良事件.
结论:
- 奥比努图祖马布在渐进性IgAN中显示了初步的疗效和有利的安全概况.
- 持续的B细胞耗尽与obinutuzumab可能有利于Igan患者.
- 需要进一步的临床试验来证实这些产生假设的发现.
更多相关视频
相关概念视频
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
260
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
260
01:26Nephrotic Syndrome II : Assessment and Medical Management
200
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
200
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
488
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
488
01:24Chronic Kidney Disease II: Clinical Manifestations
552
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
552
01:24Nephrotic Syndrome I : Introduction
499
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
499
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
490
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
490